Back to Journals » Research and Reports in Urology » Volume 2

Update on tolterodine extended-release for treatment of overactive bladder

Authors Omotosho T, Chen G

Published 23 November 2010 Volume 2010:2 Pages 185—191


Review by Single anonymous peer review

Peer reviewer comments 3

Tola Omotosho, Chi Chiung Grace Chen
Women’s Center for Pelvic Health, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, USA

Abstract: Overactive bladder is a prevalent condition which negatively impacts quality of life and puts a significant economical burden on society. First-line therapy often includes pharmacotherapy with antimuscarinic medications, and numerous research studies have demonstrated that tolterodine extended-release (ER) is an efficacious and tolerable formulation of this class of medication. This review provides an update on the clinical use of tolterodine ER, detailing the current literature on its efficacy, tolerability, adverse effects, and comparability with other commonly prescribed medications for the treatment of overactive bladder.

Keywords: antimuscarinics, efficacy, quality of life, overactive bladder, tolterodine, urgency, urge urinary incontinence

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.